In WALTHAM, Mass., on January 30, 2026, Crescent Biopharma, Inc. announced the approval by its Compensation Committee of the grant of options to purchase 117,339 shares of the Company’s ordinary shares. These options were provided as equity inducement awards to five non-executive employees under the Inducement Plan. The approval was granted on January 29, 2026, and each employee's acceptance of employment with Crescent was contingent on these options as per Nasdaq Listing Rule 5635(c)(4). Crescent is a Nasdaq-listed clinical-stage biotechnology company focused on advancing cancer therapies.